logo
Share SHARE
FONT-SIZE Plus   Neg

Forest Labs, Pierre Fabre Report Results In Phase III Trial Of Levomilnacipran

Forest Laboratories, Inc. (FRX) and Pierre Fabre Medicament announced positive top-line results in a Phase III clinical trial of levomilnacipran, an investigational agent for the treatment of adults with major depressive disorder, or MDD.

Treatment with levomilnacipran significantly reduced depression symptoms in patients with MDD versus placebo, as early as week one and at each subsequent visit as measured by the Montgomery-Asberg Depression Rating Scale-Clinician Rated. Levomilnacipran was generally well-tolerated in this study. The premature discontinuation rates were 25 percent for levomilnacipran and 21 percent for placebo. The most common adverse events observed in the levomilnacipran group were nausea, dizziness and constipation.

Results from an additional placebo-controlled Phase III fixed-dose study are expected in Spring 2012.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Orange SA declined around 3 percent in the morning trading in Paris after the French telecom major reported Tuesday weak restated EBITDA, a key earnings metric, in its home country in the first half, as well as weak EBITDA margin. Group restated EBITDA, however, increased with higher revenues, and the company posted significantly higher net profit, benefited by the sale of EE. Casino operator Las Vegas Sands Corp. (LVS), Monday said its second-quarter profit dropped from last year, hurt largely by continued challenging environment in the high-end gambling business in Macao, China. Earnings for the quarter fell short of Wall Street expectations, as did revenues. Second-quarter... Analog chip maker Texas Instruments Inc. (TXN), Monday reported a 12 percent jump in profit for the second quarter, driven largely by better cost control and higher revenues. Earnings for the quarter trumped analysts' expectations, as did revenues. The company also detailed a strong outlook for the third...
comments powered by Disqus
Follow RTT